Carter Todd Alfred 4
4 · Voyager Therapeutics, Inc. · Filed Feb 10, 2026
Research Summary
AI-generated summary of this filing
Voyager (VYGR) CSO Carter Todd Alfred Receives RSUs & Option
What Happened Carter Todd Alfred, Chief Scientific Officer of Voyager Therapeutics (VYGR), received equity awards on February 6, 2026: 33,000 restricted stock units (RSUs) and a stock option covering 154,000 shares. Both grants were reported on a Form 4 filed February 10, 2026. The reported acquisition price for both items is $0.00, indicating these were compensation awards rather than open-market purchases.
Key Details
- Transaction date: February 6, 2026; Form 4 filed February 10, 2026 (appears timely).
- Awards reported:
- 33,000 RSUs (F1) — acquisition code A; reported price $0.00.
- Option covering 154,000 shares (derivative grant, code A) — reported price $0.00.
- Vesting:
- RSUs vest over 3 years: 1/3 on the one-year anniversary, then 1/3 each year thereafter, subject to continued service (F1).
- Option vests over 4 years: 1/48th vests after one month and monthly thereafter, subject to continued service (F2).
- Shares owned after the transaction: not specified in the provided filing excerpt.
- No cash was paid for the awards; fair value or exercise price for the option (if any) is not reported here.
- No indication in the filing of a 10b5-1 plan, tax-withholding sale, or late filing code.
Context These entries are grants of compensation (RSUs and an option grant), not purchases or sales. Such awards are common for executive compensation and do not by themselves indicate the insider is buying or selling shares in the market. The option is a derivative grant (not an exercise); any future value to the insider depends on vesting and, for the option, its exercise price and Voyager's future stock price.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-06+33,000→ 156,718 total - Award
Stock Option (Right to Buy)
[F2]2026-02-06+154,000→ 154,000 totalExercise: $3.68Exp: 2036-02-06→ Common Stock (154,000 underlying)
Footnotes (2)
- [F1]Consists of shares of common stock issuable under an aggregate of 33,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.
- [F2]This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.